Screener
TG Therapeutics TGTX Debt Issuance Proceeds
Debt Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfDebt.
The source filing: TG Therapeutics’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-015246
| Line item | Three months ended / March 31, 2026 | Three months ended / March 31, 2025 |
|---|---|---|
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Payment of loan payable | (255,000) | — |
| Proceeds from exercise of options | 763 | 21 |
| Proceeds from debt financings, net of debt discount costs | 747,656 | — |
| Financing costs paid | (2,598) | — |
| Purchase of treasury stock | (99,992) | (6,123) |
| Net cash provided by (used in) financing activities | 390,829 | (6,102) |
| NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | 363,071 | (47,751) |
Document
FAQ
- What is TG Therapeutics's debt issuance proceeds?
- TG Therapeutics (TGTX) reported debt issuance proceeds of $747.66M in Q1 2026.
- What is the long-term trend for TG Therapeutics's debt issuance proceeds?
- Over 2 years (2021 to 2025), TG Therapeutics's debt issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $70M to $0.
- What does debt issuance proceeds mean?
- Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.
Ask your AI about TG Therapeutics's debt issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude